Spoken Alpha
ANAVEX LIFE SCIENCES CORP.
Anavex Life Sciences develops biopharmaceutical compounds targeting central nervous system diseases by activating sigma-1 receptors to restore cellular balance.
ANAVEX LIFE SCIENCES CORP is a Healthcare company operating in Biotechnology with a $242.9M market cap.
AVXL beat consensus EPS by 1.0% in Q3 FY2026, reported Aug 24, 2026.
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AVXL.
$ curl https://api.spokenalpha.com/v1/companies/AVXLFAQ
Spoken Alpha indexes AVXL's earnings call transcripts at https://spokenalpha.com/companies/AVXL. Each call links to attributed speakers and parsed analyst Q&A.
ANAVEX LIFE SCIENCES CORP. (AVXL) held its most recent earnings call on 2026-02-09, covering fiscal Q1 2026.
ANAVEX LIFE SCIENCES CORP. (AVXL) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-08-24 | $0.08 | $-0.08 | +100.0% | $0 | — | — | EODHD |
| Q2 FY2026 | 2026-06-29 | $-0.13 | $-0.07 | -85.7% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-02-08 | $-0.06 | $-0.11 | +45.5% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-11-24 | $-0.11 | $-0.14 | +22.9% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-08-11 | $-0.16 | $-0.14 | -14.3% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-05-12 | $-0.13 | $-0.15 | +13.3% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-02-11 | $-0.14 | $-0.17 | +17.6% | $0 | — | — | EODHD |
| Q4 FY2024 | 2024-11-24 | $-0.14 | $-0.17 | +17.6% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-24 | $-0.14 | $-0.17 | +17.6% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-0.14 | $-0.18 | +22.2% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-02-06 | $-0.11 | $-0.15 | +26.7% | $0 | — | — | EODHD |
| Q4 FY2023 | 2023-11-26 | $-0.12 | $-0.15 | +20.0% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-08-07 | $-0.14 | $-0.17 | +17.6% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-05-08 | $-0.17 | $-0.18 | +5.6% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-02-06 | $-0.17 | $-0.19 | +10.5% | $0 | — | — | EODHD |
| Q4 FY2022 | 2022-11-27 | $-0.18 | $-0.16 | -12.5% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-08-08 | $-0.16 | $-0.16 | 0.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-05-09 | $-0.14 | $-0.17 | +17.6% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-02-08 | $-0.14 | $-0.16 | +12.5% | $0 | — | — | EODHD |
| Q4 FY2021 | 2021-11-23 | $-0.15 | $-0.14 | -7.1% | $0 | — | — | EODHD |
Source: EODHD. AVXL reported actuals as published; sparse fields render as —.